Clinical trials: Refractory Acute Leukemia
B-ALL
Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia
This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD19 CAR-T cell in the treatment of recurrent or refractory B-ALL
- Trial name
- NCT04546893
- Testing
- CD19 CAR-T
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS
This is the first study of the safety of increasing dose levels of AEB1102 in patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
- Trial name
- NCT02732184
- Testing
- Co-ArgI-PEG modified human arginase I
- Where
- 10 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- Immedica Pharma AB
Leukemia, Myelodysplastic Syndromes
Chemotherapy in Treating Patients Who Have Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating patients who have hematologic…
- Trial name
- NCT00004047
- Testing
- exatecan mesylate
- Where
- United States
- Sponsor
- Daiichi Sankyo
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
This is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemotherapy, consolidation chemotherapy, post bone marrow transplantation…
- Trial name
- NCT03250338
- Testing
- Crenolanib, Cytarabine, Mitoxantrone
- Where
- 62 sites in United States, Canada and 4 more
- Volunteers
- 106 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Relapsed/Refractory AML
Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
This bridging study will evaluate the efficacy of uproleselan, a specific E-selectin antagonist, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients, compared to chemotherapy alone.
- Trial name
- NCT05054543
- Testing
- Uproleselan
- Where
- 2 sites in China
- Volunteers
- 140 people
- Sponsor
- Apollomics Inc.
AML With Gene Mutations
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia
This is a clinical study aiming to assess pharmacokinetics, pharmacodynamics and preliminary efficacy of ZE46-0134 in patients with FLT3 and spliceosome mutated Relapsed or Refractory Acute Myeloid Leukemia
- Trial name
- NCT06366789
- Testing
- ZE46-0134
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 150 people
- Sponsor
- Lomond Therapeutics Holdings, Inc.
Acute Lymphoblastic Leukemia, CD19 Positive
CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
This is a single center,randomized ,two-cohorts, open-label ,phase 1/2 study to evaluate the efficacy and safety of T cells expressing CD19 chimeric antigen receptors treatment for relapsed/refractory CD19+ acute lymphoblastic…
- Conditions
- Acute Lymphoblastic Leukemia, CD19 Positive, Relapse, Refractory
- Trial name
- NCT03275493
- Testing
- CD19 CAR-T cells, CD19 CAR-T cells with CRS suppression technology
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Acute Myeloid Leukemia, Leukemia, Acute Myeloid
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus…
- Conditions
- Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute
- Trial name
- SIERRA (NCT02665065)
- Testing
- Iomab-B, Conventional Care, HCT
- Where
- 24 sites in United States, Canada
- Volunteers
- 153 people
- Sponsor
- Actinium Pharmaceuticals
Acute Myeloid Leukemia (AML)
Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
This single-arm, open-label phase I trial evaluates the safety and tolerability of ICG415, autologous CAR-T cells targeting CD33 and CLL1, in patients with relapsed or refractory acute myeloid leukemia (AML).
- Trial name
- ICG415-AML-01 (NCT07668557)
- Testing
- Anti-CD33-CLL1 CAR-T cells (ICG415) following lymphodepleting fludarabine and cyclophosphamide
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- iCell Gene Therapeutics
Acute Myeloid Leukemia, Lymphoid Leukemia
Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients
The study will be a prospective open-label single-center study in previously treated patients with Acute Myeloid Leukemia (AML) or Acute Lymphoid Leukemia (ALL).
- Trial name
- NCT02462265
- Testing
- Oshadi D & Oshadi R;, salvage therapy cytosar and mitoxantrone
- Volunteers
- 15 people
- Sponsor
- Oshadi Drug Administration
Treatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)
This is an open-label, multi-cohort, multi-center Phase Ib/II clinical study to evaluate the tolerance and efficacy of Mitoxantrone Hydrochloride liposome injection combined with cytarabine in patients with Acute Myeloid Leukemia…
- Trial name
- NCT05100303
- Testing
- Mitoxantrone Hydrochloride liposome injection, Cytarabine (LoDAC)
- Where
- China
- Volunteers
- 58 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
The purpose of this study is to evaluate the efficacy of daratumumab in addition to standard chemotherapy in pediatric participants with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LL)…
- Trial name
- NCT03384654
- Testing
- Daratumumab, Vincristine, Prednisone
- Where
- 53 sites in United States, Belgium and 8 more
- Volunteers
- 47 people
- Sponsor
- Janssen Research & Development, LLC
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma
Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
The major aim of this research is to assess the feasibility, safety and effectiveness of CD19 CAR-T Cell Therapy for Relapsed/ Refractory Acute Lymphoblastic Leukemia/ B cell Lymphoma patients who have applied it.
- Trial name
- NCT03281551
- Testing
- PZ01 CAR-T cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Pinze Lifetechnology Co. Ltd.